TWD 32.3
(1.1%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 64.15 Million TWD | -13.28% |
2022 | 68.33 Million TWD | 129.35% |
2021 | 32.75 Million TWD | 26.45% |
2020 | 25.9 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 FY | - TWD | -13.28% |
2022 FY | - TWD | 129.35% |
2021 FY | - TWD | 26.45% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
BIONET Corp. | 147.09 Million TWD | 56.387% |
DIVA Laboratories, Ltd. | 100.31 Million TWD | 36.05% |
Genetics Generation Advancement Corp. | 50.6 Million TWD | -26.774% |
Welgene Biotech Co.,Ltd. | 26.83 Million TWD | -139.051% |
Puriblood Medical Co., Ltd. | -44.01 Million TWD | 245.748% |